Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Renal Insufficiency 1Osteosarcoma 1Neoplasms 1Lymphoma 1Leukemia 1

Interventions

3-Iodobenzylguanidine 6Magnetic Resonance Spectroscopy 5Amifampridine 5gallium 68 PSMA-11 4fludarabine phosphate 3Cyclophosphamide 3pembrolizumab 2fluorodopa F 18 2fludarabine 2carbon-11 acetate 2Whole-Body Irradiation 2Oxaliplatin 2Ga(III)-DOTATOC 2Fluorouracil 2Bortezomib 2Bone Marrow Transplantation 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2venetoclax 1veliparib 1ulocuplumab 1trametinib 1selinexor 1ponatinib 1pegfilgrastim 1omburtamab I-131 1nirogacestat 1neratinib 1navitoclax 1motexafin gadolinium 1mifamurtide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Expanded_access × Carboxypeptidases × Clear all
NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡